Praxis Fuer Dermatologie Und Venerologie
- Address
- Hauptstrasse 36a, Innere Neustadt, 01097 Dresden, Germany
Praxis Fuer Dermatologie Und Venerologie - Specialized Dermatology Research Center
Praxis Fuer Dermatologie Und Venerologie is a specialized dermatology and venereology clinical research center with extensive expertise in investigating innovative therapies for complex skin disorders. The center demonstrates particular proficiency in conducting Phase 3 clinical trials across a diverse spectrum of dermatological conditions, ranging from common inflammatory skin diseases to rare autoimmune disorders.
- Chronic inflammatory skin conditions including moderate-to-severe plaque psoriasis and atopic dermatitis
- Novel topical and systemic therapies including JAK inhibitors, biologic agents, and corticosteroid formulations
- Specialized conditions such as nonsegmental vitiligo, palmoplantar pustulosis, and papulopustular acne
- Long-term safety and efficacy evaluations of emerging dermatologic treatments
The research center has established significant expertise in evaluating both topical formulations and systemic oral therapies, with particular focus on comparative effectiveness studies and dose-optimization trials. Their comprehensive portfolio includes investigations of next-generation immunomodulatory agents, such as ritlecitinib for vitiligo, TAK-279 and BMS-986165 for psoriasis, and nemolizumab for atopic dermatitis. The center's participation in multiple long-term extension studies underscores their commitment to understanding the sustained safety profiles and durability of treatment responses, making them a valuable contributor to advancing evidence-based dermatological care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Dermapharm AG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Dermapharm AG3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis Fuer Dermatologie Und Venerologie
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis | Novartis Pharma AG | Phase II | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucravacitinib | 3 | Unknown | 2019-12-12 | 2026-05-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.